News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients with hormone receptor-positive/human epidermal ...

Neoadjuvant and adjuvant therapy for early-stage breast cancer Research ... of adjuvant endocrine therapy are recommended to receive endocrine therapy alone or endocrine therapy plus targeted ...

Opens in a new tab or window An FDA panel on Thursday endorsed a cryoablation system as an alternative to surgery for some early breast cancer ... with adjuvant endocrine therapy outweigh the ...

Treatment for breast cancer can come in many forms. In addition to surgery to remove cancerous tissue and radiation therapy, ...

"Today, many people diagnosed with HR+/HER2- early breast cancer in Europe lack options beyond endocrine therapy to help ... Kisqali® (ribociclib) is a selective cyclin-dependent kinase inhibitor ...

Erika Hamilton, MD, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer.

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast ... Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer ... Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.1 ...

Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of ...